Should we consider MMF therapy after rituximab for nephrotic syndrome?

被引：19

作者：

Filler, Guido ^{[1
,2
,3
]}

Huang, Shih-Han Susan ^{[4
]}

Sharma, Ajay P. ^{[2
]}

机构：

[1] Univ Western Ontario, London Hlth Sci Ctr, Dept Pediat, Childrens Hosp, London, ON N6A 5W9, Canada

[2] Schulich Sch Med & Dent, Dept Pediat, London, ON N6A 5W9, Canada

[3] Univ Western Ontario, Schulich Sch Med & Dent, Dept Pathol & Lab Med, London, ON N5A 5A5, Canada

[4] Schulich Sch Med & Dent, Dept Med, London, ON N6A 5W9, Canada

来源：

PEDIATRIC NEPHROLOGY | 2011年 / 26卷 / 10期

关键词：

Rituximab; Steroid-dependent nephrotic syndrome; Evidence-based treatment; MMF; SEGMENTAL GLOMERULOSCLEROSIS; MYCOPHENOLATE-MOFETIL; CYCLOSPORINE; REMISSION; TRIAL; CHILDREN;

D O I：

10.1007/s00467-011-1894-x

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

The management of steroid-dependent nephrotic syndrome, especially in patients who have failed to respond to cytotoxic drugs, such as cyclophosphamide, remains challenging. Rituximab represents a new (off-label) therapeutic option. In a significant portion of patients, it has a short serum half-life following the recovery of CD20-positive cells. The addition of mycophenolate mofetil (MMF) as a maintenance therapy is also an attractive option, but one which requires testing in a prospective randomized clinical trial with therapeutic drug monitoring and mechanistic ancillary studies.

引用

页码：1759 / 1762

页数：4

共 24 条

[1]

[Anonymous], 1978, KIDNEY INT, V13, P159

[2] Severe Ulcerative Colitis After Rituximab Therapy [J].

Ardelean, Daniela S. ;

Gonska, Tanja ;

Wires, Shannon ;

Cutz, Ernest ;

Griffiths, Anne ;

Harvey, Elizabeth ;

Tse, Shirley M. L. ;

Benseler, Susanne M. .

PEDIATRICS, 2010, 126 (01) :E243-E246

[3]

BEATTIE TJ, 1991, LANCET, V337, P1555

[4] Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy [J].

Benz, K ;

Dötsch, J ;

Rascher, W ;

Stachel, D .

PEDIATRIC NEPHROLOGY, 2004, 19 (07) :794-797

[5] A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis [J].

Cattran, DC ;

Appel, GB ;

Hebert, LA ;

Hunsicker, LG ;

Pohl, MA ;

Hoy, WE ;

Maxwell, DR ;

Kunis, CL .

KIDNEY INTERNATIONAL, 1999, 56 (06) :2220-2226

[6] Fatal pulmonary fibrosis after rituximab administration [J].

Chaumais, Marie-Camille ;

Garnier, Arnaud ;

Chalard, Francois ;

Peuchmaur, Michel ;

Dauger, Stephane ;

Jacqz-Agrain, Evelyne ;

Deschenes, Georges .

PEDIATRIC NEPHROLOGY, 2009, 24 (09) :1753-1755

[7] To what extent does the understanding of pharmacokinetics of mycophenolate mofetil influence its prescription [J].

Filler, G ;

Lepage, N .

PEDIATRIC NEPHROLOGY, 2004, 19 (09) :962-965

[8] Treatment of nephrotic syndrome in children and controlled trials [J].

Filler, G .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 :75-78

[9] Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult:: First case report and pathophysiological considerations [J].

Francois, Helene ;

Daugas, Eric ;

Bensman, Albert ;

Ronco, Pierre .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2007, 49 (01) :158-161

[10] Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil [J].

Gellermann, J ;

Querfeld, U .

PEDIATRIC NEPHROLOGY, 2004, 19 (01) :101-104

← 1 2 3 →